Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP4F2 | P78329 | 1/20 | 0.41 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.41 |
| ▸ | KCNA5 | P22460 | 5/20 | 0.40 |
| ▸ | MAOB | P27338 | 8/20 | 0.39 |
| ▸ | MAOA | P21397 | 6/20 | 0.39 |
| ▸ | ACHE | P22303 | 4/20 | 0.39 |
| ▸ | BCHE | P06276 | 3/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30242615 | 1.00 | CYP4F2 (0.41) | CYP4F2CYP4A11KCNA5MAOBMAOA | |
| SCHEMBL30242527 | 0.92 | PLA2G2A (0.38) | CYP4F2CYP4A11KCNA5MAOBMAOA | |
| SCHEMBL26630592 | 0.91 | CYP4F2 (0.39) | CYP4F2CYP4A11KCNA5ACHEBCHE | |
| SCHEMBL24012965 | 0.90 | MAOB (0.41) | CYP4F2CYP4A11KCNA5MAOBMAOA | |
| SCHEMBL24012869 | 0.85 | CYP4F2 (0.37) | CYP4F2CYP4A11 | |
| SCHEMBL24013113 | 0.85 | CYP4F2 (0.52) | CYP4F2CYP4A11MAOBMAOA | |
| SCHEMBL24012601 | 0.85 | CYP4F2 (0.37) | CYP4F2CYP4A11 | |
| SCHEMBL27032051 | 0.84 | CYP4F2 (0.42) | CYP4F2CYP4A11MAOBMAOAACHE | |
| SCHEMBL24012649 | 0.82 | CYP4F2 (0.40) | CYP4F2CYP4A11 | |
| SCHEMBL27032476 | 0.82 | CYP4F2 (0.40) | CYP4F2CYP4A11MAOBMAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230357269-A1 | NEW MACROCYCLIC LRRK2 KINASE INHIBITORS | ONCODESIGN PRECISION MEDICINE (FR) | 2023-11-09 | — | — | US | disclosed |
| US-20230357269-A1 | NEW MACROCYCLIC LRRK2 KINASE INHIBITORS | ONCODESIGN PRECISION MEDICINE (FR) | 2023-11-09 | — | — | US | disclosed |
| CN-115996932-A | New macrocyclic LRRK2 kinase inhibitors | 法国施维雅药厂 | 2023-04-21 | — | — | CN | disclosed |
| WO-2021224320-A1 | NEW MACROCYCLIC LRRK2 KINASE INHIBITORS | LES LABORATOIRES SERVIER (FR) | 2021-11-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230357269-A1 | NEW MACROCYCLIC LRRK2 KINASE INHIBITORS | LRRK2, RIN1, GRK3 | CYP4F2 4470/4885CYP4A11 4478/4885KCNA5 1961/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.